Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12714MR)

This product GTTS-WQ12714MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12714MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4339MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ10744MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ864MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ6036MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ2414MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 145
GTTS-WQ13347MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ15824MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ1268MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-414
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW